Imagion Biosystems has updated investors by lodging the latest version of its corporate presentation visuals with the Australian Securities Exchange. Content includes overviews of MagSense® Technology, the medical needs for clinical MagSense imaging, market sizes and growth rates, development milestones, and more.
View the 25 October 2017 Investor Update.
Imagion Biosystems receives AU$3.5 million in R&D tax incentives
September 19, 2023
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it